RIO Trial

BHIVA Spring Conference 2025, 23 April – 25 April 2025, Brighton, UK: HIV Medicine: Vol 26, No S2 Click on the title to browse this issue

Abstracts from the Spring 2025 @bhiva.bsky.social conference (open access):

onlinelibrary.wiley.com/toc/14681293...

#BHIVA25

i-base.info/htb/50971

Want to find out more about RIO?

The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.

Read more about it here ⬆️

@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs

Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban!

#KeystoneSymposium #HIVcure2025

Chart showing 3 patterns of viral rebound in people in the RIO study

People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance.

#KeystoneSymposium #HIVcure2025

Ming Lee presenting his conference talk titled 'The use of long-acting broadly neutralising antibodies to confer HIV viral control'

Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.

#KeystoneSymposium #HIVcure

La lueur d'espoir qu'il me fallait pour commencer la journée :)
Je ferai peut-être partie de la dernière génération à devoir vivre avec le VIH sur le long terme.
La recherche avance ✊💉🏥

Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot The day before the Conference on Retroviruses and Opportunistic Infections (CROI 2025) opened in San Francisco on Sunday, there was a community workshop on HIV cure science, at which Dr Michael Peluso...

Promising results from 2 HIV cure studies using antibodies.
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...

As RIO and other groups have shown, bNAbs may be most promising as an immunotherapeutic intervention to enhance immun rasponsew, rather than as ART treatment. #CROI2025

i-Base graphic. The main text in red and dark blue, on a light blue blue background, reads: CROI 2025. RIO study early results. Viral load remains undetectable off-ART, plus possible vaccine-like HIV cure. Below, in white on a burnt orange background, text reads, San Francisco, California. 9th to 12th March. On top of this is a faint image of the Golden Gate Bridge. In the top left corner is a URL: I hyphen base dot info. In the top right corner is a box made of blue, yellow and red blocks. White text on it reads, HTB news. 2025.

Exciting early riotrial.bsky.social‬ results at #CROI2025:i-base.info/htb/50530

New #bNABs so far successful in keeping viral load undetectable in some participants off #HIVtreatment.

Also the first time we’ve seen bNABs cause vaccine-like immune response.

#RIOtrial #teropavimab #zinlirvimab

RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.

Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.

Our ICTU Statistician Louise-Rae Cherrill is at #CROI2025 for the presentation of exciting results of the ICTU-managed @riotrial.bsky.social with promising advances in #HIVTreatment driven by immune-based therapies www.imperial.ac.uk/news/261858/...

YouTube video by IAS-USA CROI 2025 Monday (March 10) Press Conference

www.youtube.com/watch?v=QnFb...

RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.

Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)

RIO HIV Trial - Viral suppression off ART using dual bNAb therapy RIO is looking at whether a new type of treatment, called bNAbs can keep viral load undetectable without antiretroviral treatment (ART)

You can find out more about the latest study developments at riotrial.org

The study is still ongoing, with follow-up of the participants still part of the protocol continuing until 2027. Final results of all remaining protocol defined endpoints are anticipated towards the end of 2027, while a new arm of the study will also be opening soon to new participants.

While these results are still preliminary, they suggest bNAb therapies could offer a new path to managing HIV and possibly lead to a cure.

This study is the first to show sustained viral control using these immune-based therapies. The bNAbs not only targeted HIV directly but also stimulated the immune system, with some participants achieving undetectable levels of HIV in their reservoirs.

The results showed that 75% of participants who received bNAbs were able to control the virus for 20 weeks, compared to those who received a placebo over the same timeframe.

Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.

Immune response may be harnessed to control HIV, RIO study shows  | Imperial News | Imperial College London New antibody therapies could offer alternative to current treatments.

New hope for #HIV treatment?

Research led by @imperialcollegeldn.bsky.social unveils promising trial results showing antibody therapies could control HIV without daily medication.

Read more 👇 imperial.ac.uk/news/261858/...
@imperialinfect.bsky.social

RIO Study: New antibody therapies could offer alternative to current treatments – NIHR Imperial Biomedical Research Centre <p>Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies.</p>

The @riotrial.bsky.social shows that immune-based therapy can sustain viral control in multiple HIV participants, allowing them to stop daily antiretroviral medication for over a year, providing an alternative to current treatments.

@imperialmed.bsky.social

Full article 👇
tinyurl.com/29rsb458

BNAbs we're safe with no serious adverse events associated with study drug or ATI.

Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.

Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.

Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.

Immune response may be harnessed to control HIV, RIO study shows  | Imperial News | Imperial College London New antibody therapies could offer alternative to current treatments.

Early trial results unveiled by Imperial researchers show exciting advances in HIV treatment.

For the first time, immune-based treatments have managed to control the virus in patients for long periods, without the need for antiretrovirals.

Find out more 🔽

www.imperial.ac.uk/news/261858/...

Prof Sarah Fidler, RIO Chief Investigator, presenting the primary outcome results at the CROI Conference yesterday, 10 Mar 2025.

RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.

Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.

The RIO Trial - using a new immune-based therapy to treat HIV This video is about a new HIV study called RIO. It uses a new immune-based therapy to treat HIV. The study is open to people who started HIV treatment soon after…

Hi everyone! We're very excited about joining the Bluesky community! This video explains our trial design and was coordinated by the Leadership group members: Simon Collins, Sarah Fidler, John Frater, Ming Lee and Hanna Box.
#hiv #riotrial #bNAbs #CROI